Please assess the completion status of the following clinical trial:

Trial Title: IM Olanzapine Versus Haloperidol or Midazolam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.~Exclusion Criteria:~* Patients will be excluded if there are~  1. known hypersensitivity or contraindication to the study drugs~ 2. reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)~ 3. known pregnancy~ 4. acute alcohol withdrawal~ 5. patients aged\>75 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
- Haloperidol (Type: ACTIVE_COMPARATOR): intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
- Midazolam (Type: ACTIVE_COMPARATOR): intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).